Table 2.

Multivariate survival analyses of the immunological biomarkers affecting crude survival in the total cohort and Lynch syndrome subset using Cox propotional hazard model.

	Total cohort (N = 236)*			Lynch syndrome (N = 141)**
Variable	HR	95% CI	P	HR	95% CI	P
CD3
Low vs. high	2.5	1.4–4.6	0.002	3.4	1.6–7.3	0.002
CD8
Low vs. high	1.6	0.9–2.8	0.122	2.0	1.0–4.2	0.058
CD68
Intermediate vs. high	1.9	0.9–4.1	0.065	3.4	0.9–12.3	0.083
Low vs. high	2.1	1.0–4.4	0.043	6.5	1.8–23.3	0.004
B2M
Normal vs. loss	3.4	1.4–8.7	0.009	3.5	1.2–10.1	0.022
Normal vs. loss***	3.7	1.3–10.1	0.012	–	–	–
PD-L1+ TC
5–9% vs. ≥ 10%	1.0	0.2–4.9	0.953	–	–	–
< 5% vs. ≥ 10%	1.5	0.3–7.3	0.635	–	–	–
PD-L1+ TIIC
5–9% vs. ≥ 10%	3.5	0.7–17.3	0.117	–	–	–
< 5% vs. ≥ 10%	4.7	0.9–23.7	0.059	–	–	–
5–9% vs. ≥ 10%***	3.5	0.6–19.0	0.146	–	–	–
< 5% vs. ≥ 10%***	7.9	1.5–40-4	0.013	–	–	–

Abbreviations: HR, hazard ratio; CI, confidence intervals; TC, tumor cells; TIIC, tumor-infiltrating immune cells; MMR, mismatch repair; TNM, tumor node metastasis.

*Analyses were adjusted for MMR status, TNM stage, sex and age.

**Subset analyses in the Lynch syndrome cohort were adjusted for TNM stage, sex and age.

***Analyses were adjusted for MMR status, TNM stage, sex, age and CD8 expression levels.